<DOC>
	<DOCNO>NCT01288742</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration TMC435 single-dose pharmacokinetics digoxin rosuvastatin , effect single dose digoxin rosuvastatin steady-state pharmacokinetics TMC435 . Steady state term mean drug give long enough plasma concentration remain subsequent dose . TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body , eliminate body .</brief_summary>
	<brief_title>TMC435-TiDP16-C108 - A Study Healthy Volunteers Investigating Pharmacokinetic Interaction Between TMC435 Digoxin Between TMC435 Rosuvastatin</brief_title>
	<detailed_description>TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection , combination Peg-IFN ( pegylated interferon ) RBV ( ribavirin ) . Digoxin rosuvastatin express liver intestine mediate transport drug blood circulation . The result study provide dose recommendation TMC435 digoxin , rosuvastatin , substrates use drug transporter molecule , coadministered . This Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( sequence treatment study medication assign chance ) , crossover trial 32 healthy volunteer investigate pharmacokinetic interaction TMC435 , steady state , digoxin rosuvastatin single dose . The volunteer allocate one two panel . In Panel 1 , volunteer receive two treatment ( Trts A B ) randomize order . Volunteers receive digoxin 0.25 mg daily 1 day ( Trt A ) TMC435 150 mg daily 7 day ( Trt B ) 0.25 mg digoxin daily 1 day ( Trt B ) . In Panel 2 , volunteer receive two treatment ( Trts C D ) randomize order . Volunteers receive rosuvastatin 10 mg daily 1 day ( Trt C ) TMC435 150 mg daily 7 day ( Trt D ) rosuvastatin 10 mg daily 1 day ( Trt D ) . In panel , washout period ( period study drug take , order medication eliminate body start new treatment ) least 14 day last intake study medication one session first intake study medication subsequent session . Pharmacokinetic profile three compound determine blood sample take regular interval study . Safety tolerability assess study period follow . Blood urine sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , medication intake Day -1 Day 1 ( Trts A , B , C , D ) , Day 2 ( Trts A C ) , medication intake 6 hour postdose ( vital sign ECG ) Day 7 ( Trts B D ) , Day 8 ( Trts B D ) 2 follow visit 1 week 4-5 week last dose study medication last session . A physical examination perform screening , Day -1 ( = day first medication intake session panel ) Day 2 Trts A C , Day -1 Day 8 Trts B D 2 follow-up visit . Each volunteer part one panel follow 2 treatment ( Trt ) period , minimum 14 day apart . Trt period Trts A C - 5 day ; Trt period Trts B D - 11 day . Trt A B = Panel 1 , Trt C D = Panel 2 . A single , oral dose digoxin ( 0.25 mg ) rosuvastatin ( 10 mg ) give Trt A Trt C , respectively . Multiple dos TMC435 ( 150 mg ) 7 day give TrtB D , single dose digoxin rosuvastatin Day7 , respectively .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Nonsmoker chew tobacco least 6 month Body Mass Index 18.0 30.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test , vital sign , electrocardiogram Infection hepatitis A , B C virus Infection human immunodeficiency virus ( HIV ) History , current medical condition could impact safety participant study Having previously participate multipledose trial TMC435 Having previously participate 3 singledose trial TMC435 History rhabdomyolysis muscle abnormality upon statin intake ( Panel 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>TMC435-TiDP16-C108</keyword>
	<keyword>TMC435-C108</keyword>
	<keyword>TMC435</keyword>
	<keyword>HPC</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>